Glycyrrhetinic Acid and Acute Irritant Dermatitis
ConditionIrritant Contact Dermatitis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Split, School of Medicine
About this trial
Irritant dermatitis is one of the most common inflammatory skin disorders, caused by exposure to external substances that induce inflammation and immune activation. Standard management includes avoidance of irritants, restoration of the skin barrier using emollients, and the application of anti-inflammatory drugs such as topical corticosteroids. However, due to the risks associated with long-term corticosteroid use, there is an interest in developing emollient formulations enriched with bioactive compounds possessing anti-inflammatory properties. Among those promising compounds is glycyrrhetinic acid.
18β-Glycyrrhetinic acid, a bioactive component of licorice root extract, exhibits potent anti-inflammatory and antioxidant effects. Topical application has demonstrated beneficial outcomes in conditions such as atopic dermatitis, acne, pruritus, and UVB-induced skin damage. Its proposed mechanisms of action include inhibition of key inflammatory enzymes (COX, 5-LOX, iNOS) and promotion of skin regeneration through stimulation of aquaporin-3 expression and enhancement of epidermal turnover.
Topical application of formulations containing 18β-glycyrrhetinic acid will improve skin parameter disturbances caused by irritation induced with sodium lauryl sulfate.
This study aims to evaluate the effects of 18β-glycyrrhetinic acid on human skin parameters in an acute irritant dermatitis model induced by sodium lauryl sulfate, providing further insight into its potential role as an anti-inflammatory and barrier-restoring agent.
Funding:
Funded by the European Union - NextGenerationEU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy adult participants aged 18 years or older, of any sex.
Intact, healthy skin at the test sites.
No use of systemic or topical corticosteroids, immunomodulators, or antihistamines within the previous three months.
No use of topical emollients on the test sites within the previous seven days.
Disqualifiers
Pregnant women, women suspected of being pregnant, and breastfeeding women.
Non-compliance with the study protocol.
Voluntary withdrawal or personal decision not to continue participation.
Trial design
Design model
Parallel
Treatments tested in this trial
SLS induced irritation
Procedure/SurgerySkin irritation will be induced on 4 defined test sites on one forearm (randomly selected forearm) using 60 uL of 1% w/v sodium lauryl sulfate (SLS) aqueous solution under occlusion for a defined period to create a controlled model of acute irritant dermatitis. The contralateral forearm will remain untreated and serve as intact skin for comparison. Following the induction phase, all test products (placebo and active formulations) will be applied to both irritated and intact sites according to the treatment allocation.
No Treatment
Other interventionDesignated test area with no topical application after irritation (on the irritated forearm) and on corresponding intact skin (on the non-irritated forearm). Serves as a baseline reference for spontaneous recovery and physiological skin variability.
Placebo
Other interventionTopical formulation identical in composition to the active preparations but without glycyrrhetinic acid. Used to evaluate the effect of the formulation vehicle on skin parameters. Applied daily to designated test sites on both irritated and intact forearm areas for the duration of the study.
Lower Dose Glycyrrhetinic Acid
Other interventionTopical formulation containing a lower concentration of 18β-glycyrrhetinic acid. Designed to assess the effects of the active compound at a lower dose on skin barrier recovery and skin parameters following SLS-induced irritation. Applied daily to designated test sites on both irritated and intact forearm areas for the duration of the study.
Higher Dose Glycyrrhetinic Acid
Other interventionTopical formulation containing a higher concentration of 18β-glycyrrhetinic acid. Designed to assess the effects of the active compound at a lower dose on skin barrier recovery and skin parameters following SLS-induced irritation. Applied daily to designated test sites on both irritated and intact forearm areas for the duration of the study.
Treatment groups
30 Participants
are divided into 8 treatment groups8
Treatment groupsSee each treatment group below.
Group A: No Treatment and Intact skinOther 1 intervention
Group B: Placebo and Intact skinPlacebo comparator 1 intervention
Group C: Glycyrrhetinic Acid (lower dose) and Intact skinExperimental treatment 1 intervention
Group D: Glycyrrhetinic Acid (higher dose) and Intact skinExperimental treatment 1 intervention
Group E: No Treatment and IrritationOther 2 interventions
Group F: Placebo and IrritationPlacebo comparator 2 interventions
Group G: Glycyrrhetinic Acid (lower dose) and IrritationExperimental treatment 2 interventions
Group H: Glycyrrhetinic Acid (higher dose) and IrritationExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Transepidermal water loss
Tewameter will be used to assess skin barrier function as a measurement of the water loss (g/m2/h).
Time frame
Baseline, Irritation Assessment, 3rd, 6th, 8th and 10th day of the treatment2
Hydration
Corneometer will be used to estimate skin dryness. It is a relative measurement and uses arbitrary units (AU).
Time frame
Baseline, Irritation Assessment, 3rd, 6th, 8th and 10th day of the treatment3
Erythema
Mexameter will be used to assess erythema. It is a relative measurement and uses arbitrary units (AU).
Time frame
Baseline, Irritation Assessment, 3rd, 6th, 8th and 10th day of the treatment4
Skin elasticity
Cutometer will be used to assess skin elasticity.
Time frame
Baseline, Irritation Assessment, 3rd, 6th, 8th and 10th day of the treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Split, School of Medicine
Lead sponsor
European Union
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: